In addition to its prokinetic properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects. Mosapride also promotes neurogenesis in the gastrointestinal tract which may prove useful in certain bowel disorders. The neurogenesis is due to mosapride's effect on the 5-HT4 receptor where it acts as an agonist.
Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, malaise, nausea, diarrhea and sometimes constipation. Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on hERG transfected cells, and no effect on cardiovascular function that could be detected in tests on humans. Due to the pharmacokinetics of mosapride, it would take 1,000–3,000 times the therapeutic dose to elicit cardiovascular effects.
^Mizuta, Y; Shikuwa, S; Isomoto, H; Mishima, R; Akazawa, Y; Masuda, J; Omagari, K; Takeshima, F; Kohno, S (Nov 2006). "Recent insights into digestive motility in functional dyspepsia". Journal of Gastroenterology. 41 (11): 1025–40. doi:10.1007/s00535-006-1966-z.
^Kato, S; Morie, T; Yoshida, N (Apr 1995). "Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent". Chemical and Pharmaceutical Bulletin (Tokyo). 43 (4): 699–702. doi:10.1248/cpb.43.699.
^Kawahara I, Kuniyasu H, Matsuyoshi H, et al. (March 2012). "Comparison of effects of a selective 5-HT reuptake inhibitor versus a 5-HT4 receptor agonist on in vivo neurogenesis at the rectal anastomosis in rats". Am. J. Physiol. Gastrointest. Liver Physiol. 302 (6): G588–97. doi:10.1152/ajpgi.00284.2011. PMID22194416.
^Matsuyoshi H, Kuniyasu H, Okumura M, et al. (July 2010). "A 5-HT(4)-receptor activation-induced neural plasticity enhances in vivo reconstructs of enteric nerve circuit insult". Neurogastroenterol. Motil. 22 (7): 806–13, e226. doi:10.1111/j.1365-2982.2010.01474.x. PMID20146727.